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Abstract: Individual variations in inorganic arsenic metabolism may influence the toxic 
effects. Arsenic (+3 oxidation state) methyltransferase (AS3MT) that can catalyze the 
transfer of a methyl group from S-adenosyl-L-methionine (AdoMet) to trivalent arsenical, 
may play a role in arsenic metabolism in humans. Since the genetic polymorphisms of 
AS3MT gene may be associated with the susceptibility to inorganic arsenic toxicity, 
relationships of several single nucleotide polymorphisms (SNPs) in AS3MT with inorganic 
arsenic metabolism have been investigated. Here, we summarize our recent findings and 
other previous studies on the inorganic arsenic metabolism and AS3MT genetic 
polymorphisms in humans. Results of genotype dependent differences in arsenic 
metabolism for most of SNPs in AS3MT were Inconsistent throughout the studies. 
Nevertheless, two SNPs, AS3MT 12390 (rs3740393) and 14458 (rs11191439) were 
consistently related to arsenic methylation regardless of the populations examined for the 
analysis. Thus, these SNPs may be useful indicators to predict the arsenic metabolism via 
methylation pathways. 
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1. Introduction 
Groundwater pollution by inorganic arsenic (IA) derived from natural origin is a serious issue of 
public health in the world, especially in developing countries where clean and safe surface water is not 
available in many places. In these areas, high arsenic concentrations exceeding the WHO guideline  
(10 μg/L) for drinking [1] have been reported in the groundwater [2–4]. It is well known that IA is one 
of the carcinogenic chemicals for the human. Chronic arsenic exposure causes skin pigmentation, 
hyperkeratosis, and cancers in the skin, lung, bladder, liver, and kidney resulting in high   
mortalities [1,5,6]. 
In general, humans can metabolize ingested IA to monomethylated arsenic (MMA) and then 
dimethylated arsenic (DMA), through arsenic (+3 oxidation state) methyltransferase (AS3MT). The 
pathways are discussed in detail in a later section of this review. Urinary arsenical profile has been 
used to assess arsenic exposure and its metabolism in individuals. In general, concentration ratios of 
MMA/IA and DMA/MMA in the urine indicate first and second methylation capacity, respectively. 
The metabolic action of AS3MT is considered to have an association with accumulation profile of 
various arsenic compounds in the body and consequently with susceptibility to toxic effects of arsenic. 
Several previous epidemiological studies showed that people who had high percentage of DMA 
(%DMA) in the urine could excrete more arsenic from the body because of high arsenic methylation 
capacity [7,8]. In other epidemiological studies, high concentration or percentage of MMA in the urine 
of populations with arsenic-related diseases were reported when compared with that of healthy 
people [9–12]. 
Vahter [13] showed that relative distributions of IA, MMA, and DMA in the urine of various 
populations are generally 10–30%, 10–20%, and 60–70%, respectively. On the other hand, there are 
large variations in the arsenic metabolism at individual and population levels [7]. It is known that 
biological and environmental factors including age, sex, pregnancy, arsenic exposure level, smoking 
habits, nutritional status and diet, potentially relate to the inter-individual variation (reviewed by   
Tseng [14]). With regard to ethnic related variation, it was shown that Andes women in arsenic 
contaminated area had only a low percentage of MMA[V] (0–11%) in the urine [15], whereas residents 
ingesting arsenic through drinking water in the northeast Taiwan had an extraordinarily high 
%MMA[V] (26.9%) in the urine [16]. These results indicate that genetic polymorphisms of certain 
enzymes that can metabolize arsenic through methylation pathways may be one of factors associated 
with the variation of arsenic profiles. 
Genetic analyses of SNPs in the enzymes that may be involved in arsenic metabolism have been 
recently developed to evaluate the variation in the metabolism or toxic impacts of arsenic at individual 
or population level. We have also reported the association of arsenic metabolism-SNPs in AS3MT in 
Vietnamese [17–21]. However, a limited number of publications regarding the association of SNPs in 
AS3MT with arsenic methlyation are available. Moreover, the published results are based on 
fragmentary investigations and thus consistent conclusions have not yet been drawn. Hernandez and 
Marcos [22] have recently reviewed the role of genetic polymorphisms in enzymes related to arsenic 
metabolism including AS3MT. Thereafter, the number of publications regarding genetic 
polymorphisms dependent metabolism and toxicity of arsenic is increasing. Int. J. Mol. Sci. 2011, 12      
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In this short-review, we address the following three topics: (1) enzymatic processes of arsenic 
methylation by AS3MT; (2) associations of genetic polymorphisms in AS3MT with variation in arsenic 
methylation; (3) frequency distributions of genetic polymorphisms in AS3MT at population levels. 
Based on the summarized data, we suggest which SNPs in AS3MT gene play an important role in 
arsenic methylation. In addition, we discuss future issues to be solved. 
2. Arsenic Methylation by Human AS3MT 
Two distinct pathways of IA methylation (oxidative and reductive) have been proposed (Figure 1). 
A model of oxidative methylation of IA was proposed by Challenger [23] and Cullen and Reimer [24]. 
By the combination of oxidative methylation and other pathways, arsenate (As[V]) is transformed to 
dimethylarsinous acid (DMA[III]); arsenate (As[V]) → arsenite (As[III]) → monomethylarsonic   
acid (MMA[V]) → monomethylarsonous acid (MMA[III]) → dimethylarsinic acid (DMA[V]) → 
dimethylarsinous acid (DMA[III]) (Figure 1). However, this sequential pathway does not fully explain 
the reason why the intermediate species, DMA[V] is detected as a major arsenical in the urine of 
humans. Methylation has been considered as a detoxification process of IA, because toxicities of 
MMA[V] and DMA[V] are much lower than that of IA. On the other hand, later studies revealed that 
MMA[III] or DMA[III] are more cytotoxic and genotoxic than IA [25,26], suggesting that oxidative 
methylation of IA is a bioactivation process.  
On the contrary, Hayakawa et al. [27] reported a reductive methylation model for the metabolism of 
arsenic compounds. In this model, trivalent arsenicals are conjugated with glutathione (GSH) and then 
are methylated; As[III] → arsenotriglutathione (As[III](GS)3)  → monomethylarsenodiglutathione 
(MMA[III](GS)2)  → dimethylarsenoglutathione (DMA[III](GS)) (Figure 1). MMA[III](GS)2 and 
DMA[III](GS) are then oxidized to MMA[V] and DMA[V], respectively. Naranmadura et al. [28] 
investigated hepatic and renal metabolites of arsenic after an intravenous injection of As[III]   
(0.5 mg As/kg body weight) in rats. The authors proposed that trivalent arsenic species can bind to 
thiol groups in proteins. The protein-bound arsenicals are released from the proteins by conjugation 
with GSH to form As[III](GS)3 or MMA[III](GS)2 or DMA[III](GS) [28]. Hence, in the reductive 
methylation, MMA[V] and DMA[V] could be the end products. This hypothesis is consistent with the 
results that DMA[V] is found as a major arsenical in the urine. This sequential reaction is considered 
to be a detoxification process of IA, because of the low toxicities of MMA[V] and DMA[V].  
Through both oxidative and reductive metabolic pathways, AS3MT plays an important role on 
arsenic methylation (Figure 1). Lin et al. [29] succeeded in purifying arsenic (III) methyltransferase 
(previously called as Cyt19) from the liver cytosol of adult male Fischer 344 rats. AS3MT is an  
S-adenosyl-L-methionine dependent enzyme and could methylate trivalent arsenicals [29,30]. Human 
AS3MT gene is composed of 32-kb with 11 exons [30]. Variety of genetic polymorphisms including 
SNPs and variable number of tandem repeats (VNTRs) have been identified in this gene [30,31]. This 
indicates that these genotypes may influence the methylation capacity of arsenic compounds and 
subsequently the arsenic toxicity. Recently, Kojima et al. [32] reported that methylation of IA by 
AS3MT induces oxidative DNA damage and increase their carcinogenicity in vitro. In the following 
section, we summarize in vitro and epidemiological studies on the AS3MT genetic polymorphism-
dependent metabolism of arsenic compounds.  Int. J. Mol. Sci. 2011, 12      
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Figure 1. Proposed pathways of inorganic arsenic metabolism by oxidative and   
reductive methylation. 
 
3. Association of Arsenic Methylation with Genotypes in Human AS3MT 
Notation of SNPs in human AS3MT is individually defined among studies. In this review, we use 
the notation by SNP ID which indicates the polymorphism identification number relative to the 
location in the consensus sequence (AY817668) with the first base of the consensus number 1 and 
dbSNP rs# cluster id which is available on Search for SNP on NCBI Reference Assembly [33]. 
Chromosome positions of genetic polymorphisms in AS3MT are indicated in Figure 2. 
3.1. In Vitro Studies 
Drobna et al. [34] reported the association of genotypes in AS3MT with arsenic methylation in 
human hepatocytes. They treated primary hepatocytes from eight human donors with graded 
concentrations of As[III] (0.330 nmol/mg protein) for 24 h to evaluate the variation in arsenic 
metabolism. One of eight donor’s cells showed a higher methylation rate than other cells at a high 
exposure level (30 nmol/mg protein). The methylation rate was consistent with heterozygote of 
Met287Thr at amino acid base (14458 at nucleotide base, rs11191439) mutation of AS3MT, suggesting 
a linkage of this genotype with arsenic methylation. 
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Figure 2. Location of genetic polymorphisms in AS3MT. Dark blue rectangles   
represent exons. Chromosome positions are also indicated. Arrows show the locations of  
genetic polymorphisms. 
 
In vitro functional analysis of human AS3MT was performed by Wood et al. [30]. The authors 
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(n = 60), and identified 26 SNPs and one VNTR. Among the SNPs, three SNPs, Arg173Trp, 
Met287Thr, and Thr306Ile in the exon region were non-synonymous. In the AS3MT-expressed COS-1 
cells, which was treated with 12.5 nM As[III], the enzyme activity and immunoreactive protein 
expression of 287Thr variant of AS3MT were significantly higher than those of the wild type, whereas 
173Trp and 306Ile variants showed opposite trends. Reporter gene assays using reporter constructs 
containing different length 5’-UTR VNTR sequences of AS3MT gene demonstrated that the 
transcriptional expression of this gene depends on the number of the repeat sequence. Given these 
results, the authors suggested genetic polymorphisms in AS3MT may contribute to individual 
differences in the expression and function of AS3MT, and, consequently, to variation in the risk of 
arsenic-dependent carcinogenesis. 
3.2. Human Case Studies 
3.2.1. Mexico 
Case studies on human populations regarding the AS3MT polymorphism have recently started. 
Genetic association of AS3MT with urinary arsenic metabolite levels in residents (n = 135) ingesting 
arsenic (5.5–43.3 μg/L) through drinking water from the Yaqui Valley of Sonora, Mexico, was 
reported by Meza et al. [35]. The authors found that three unexonic SNPs (2393 at ATG offset position 
(SNP ID; AS3MT 7395, rs#; rs12767543), 7388 (AS3MT 12390, rs3740393), and 30585 (AS3MT 
35587, rs11191453)) in AS3MT were significantly associated with DMA[V]/MMA[V] in the urine of 
the entire population. Subsequent analysis showed that these relationships were observed only in 
children (7–11 years), but not for adults (18–79 years); DMA[V]/MMA[V] for AS3MT 7395 
(rs12767543) AG + AA, 12390 (rs3740393) CG + CC, and 35587 (rs11191453) CT + CC were higher 
than that for AS3MT 7395 (rs12767543) GG, 12390 (rs3740393) GG, and 35587 (rs11191453) TT, 
respectively. The linkage disequilibrium (LD) analysis revealed that these SNPs have significant LD, 
with r
2 = 0.56 for AS3MT 7395 (rs12767543) and 35587 (rs11191453), and r
2 = 0.94 for AS3MT 12390 
(rs3740393) and 35587 (rs11191453). In addition, AS3MT 35587 (rs11191453) CT + CC had 
significantly higher As[III]/MMA[V] than AS3MT 35587 (rs11191453) TT for children.  
Following the above initial study, the same group [36] found a clear association of percentage of 
(%) MMA[V] with genetic polymorphism in AS3MT 35587 (rs11191453) only for children. However, 
given that the participant selection may be biased; children of the above study belong to more 
indigenous American ancestry than adults [33,34], these age-dependent associations of genetic 
polymorphisms in AS3MT with arsenic metabolism need reconsideration.  
According to Valenzuela et al. [37], AS3MT polymorphisms may influence skin lesions caused by 
arsenic exposure through drinking water. This group investigated three SNPs, AS3MT 4602 
(rs7085104), 14458 (rs11191439, Met287Thr), and 35587 (rs11191453) in 71 individuals with skin 
lesions and 51 controls without the lesions from Zimapan, Hidalgo in Mexico. In this study area, 
medians of arsenic concentrations in wells and human urine samples were 84 μg/L and 109 μg/g 
creatinine, respectively. No significant association of AS3MT 35587 (rs11191439) was found with 
arsenic metabolism and skin disease. Among the subjects, AS3MT 4602 (rs7085104) GG carriers had 
lower %MMA[III + V], but higher %DMA[III + V] and DMA[III + V]/MMA[III + V] than   Int. J. Mol. Sci. 2011, 12      
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4602 (rs7085104) AA + AG carriers. The percentages of IA[V] and MMA[III + V] in AS3MT 14458 
(rs11191439) CT + CC carriers were significantly higher than those in AS3MT 14458 (rs11191439) TT 
carriers. This suggests that AS3MT 14458 (rs11191439) CT + CC carriers may have a poor 
methylation capacity. Interestingly, the frequency of this SNP carriers in the skin lesion group was 
marginally (p = 0.055) higher than the control subjects, suggesting that AS3MT 14458 (rs11191439) 
CT + CC may be involved in skin lesions. Although the way in which genetic polymorphism of 
AS3MT 14458 (rs11191439) affects skin lesions is not clear, it can be presumed that the skin disease 
may be related to the metabolic pathway of IA.  
Recently, from a large sample size (n = 405), Gomez-Rubio et al. [38] found significant 
associations of unexonic AS3MT 7395 (rs12767543), 12390 (rs12767543), 14215 (rs3740390), 30312 
(rs10883795), 35587 (rs11191453), 35739 (rs11191454), and 37219 (rs1046778), with urinary 
DMA[V]/MMA[V], also showing strong LD. For example, DMA[V]/MMA[V] was higher in CC 
genotype of AS3MT 30312 (rs10883795), followed by TC and TT genotypes. On the contrary, exonic 
AS3MT 14458 (rs11191439) showed no significant association with arsenic methylation, probably due 
to the small number of variants for this SNP. As described earlier, a previous study by this group 
revealed a children specific association of AS3MT genotypes with arsenic metabolism [35,36], but the 
association was also observed in adults when analyses were performed using a large number of 
subjects [38]. 
Sampayo-Reyes  et al. [39] evaluated DNA damages by a comet assay in residents who were 
exposed to IA from drinking water (1–187 μg/L) in Torreon, Coahuila, Mexico. The results revealed a 
significant positive correlation between DNA damages and urinary arsenic concentrations, suggesting 
that this population is under threat by exposure to arsenic. Furthermore, AS3MT 14458 (rs11191439, 
Met287Thr) influenced DNA damages in children; DNA damages of subjects having AS3MT 14458 
(rs11191439, Met287Thr) C allele were higher than those having T allele (p = 0.034). Hence, the 
authors suggested that the arsenic exposure through drinking water induces DNA damage and this 
effect may become more profound by AS3MT 14458 (rs11191439, Met287Thr). 
3.2.2. Argentina 
Significant relationships between genetic polymorphisms in AS3MT and arsenic metabolism in 
Argentina were reported by Schläwicke Engström et al. [40]. This group analyzed arsenic compounds 
in the urine, whole blood, and buccal cells and polymorphisms in AS3MT of 147 indigenous women 
from a village in the northern Argentinean Andes. The residents have been exposed to high levels 
(about 200 μg/L) of arsenic through drinking water. For AS3MT, nine polymorphisms (AS3MT 5019 
(rs17880342), 5194 (rs3740400), 8788 (rs17881367), 12390 (rs3740393), 12590 (rs3740392), 14215 
(rs3740390), 14458 (rs11191439), and 35991 (rs10748835)) were identified. Among these SNPs, 
intronic AS3MT 12390 (rs3740393), 14215 (rs3740390), and 35991 (rs10748835), which had a strong 
LD with each other (r
2 = 0.74–0.95), were significantly associated with the secondary methylation step 
of arsenic. For example, AA type of AS3MT 35991 (rs10748835) had a lower %MMA[V] and higher 
%DMA[V] and DMA[V]/MMA[V] ratios in the urine than the GG and GA types. They also found that 
the genotype frequencies in three SNPs in AS3MT, which had correlations with the secondary 
methylation of arsenic in a population of Argentina, were higher than those in other populations. This Int. J. Mol. Sci. 2011, 12      
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may be due to a positive selection of AS3MT genetic polymorphisms that can efficiently metabolize 
arsenic for detoxification, because these populations have suffered from arsenic toxicity for thousands 
of years [41,42].  
Recently, Schläwicke Engström et al. [43] genotyped another two SNPs, AS3MT 4602 (rs7085104) 
in 5’ terminal and AS3MT 5194 (rs3740400) in intron 1, and evaluated the influences on arsenic 
metabolism in the same subjects as in the previous cases. These SNPs comprised a strong LD   
(r
2 = 0.97) with each other and also with AS3MT 12390 (rs3740393), 14215 (rs3740390), and 35991 
(rs10748835) which were reported in the previous study [40]. This LD cluster was found only in this 
Argentinean population, but not in other HapMap populations. The SNPs, AS3MT 4602 (rs7085104) 
and 5194 (rs3740400) were clearly associated with %MMA[V] and %DMA[V].  
3.2.3. Chile 
Hernández et al. [44] investigated 50 workers who have been occupationally exposed to high levels 
of arsenic in a copper smelting plant in Chuquicamata, Chile. Mean values of exposure periods and 
total arsenic concentration in the urine of the workers were 15.55 years and 152.8 ppb, respectively. In 
this study, nine polymorphisms were found from the sequencing of exons and flanking regions of 
AS3MT gene. Three polymorphisms, AS3MT 4965 (rs17881215), exon 1: 5’-UTR (inside VNTR), and 
14458 (rs11191439) in AS3MT, which comprised one LD cluster, were significantly associated with 
the variation in %MMA[V].  
To confirm the genetic polymorphism-dependent metabolism of arsenic, Hernández et al. [45]   
re-investigated the relationships of the arsenic profile and AS3MT SNPs in larger population (n = 207), 
in which the urine had 91.26 ppb of the arsenic level on average. The results revealed that exonic 
AS3MT 14458 (rs11191439) TC + CC showed higher %MMA[V] in the urine than the wild type as 
observed in the previous study [44]. In summary, the authors concluded that AS3MT 14458 
(rs11191439) TC + CC genotypes increase the methylation capacity from IA to MMA. 
3.2.4. Central Europe 
Lindberg et al. [46] investigated the association between the genetic polymorphism in AS3MT and 
arsenic metabolism in populations from Hungary, Romania and Slovakia (n = 415) that have been 
exposed to low arsenic levels. This investigation is distinct from others, and is meaningful because 
variation of the arsenic metabolism depending on the exposure could be negligible. Even though the 
median urinary arsenic concentration of the individuals was low (8.0 μg/L), percentages of arsenic 
compounds in the urine varied widely. Through the multivariate analysis, they found that AS3MT 
14458 (rs11191439) in exon was one of the major factors that can influence arsenic metabolism; the 
TC + CC type had higher %MMA[V] and lower %DMA[V] than the TT type. This trend was much 
more pronounced in men than in women.  
3.2.5. India 
West Bengal in India is one of the most severe arsenic endemic areas in the world. It has been 
estimated that about 6,000,000 people are exposed to arsenic through the consumption of   Int. J. Mol. Sci. 2011, 12      
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groundwater [3]. However, only 300,000 individuals (5% of total exposed population) within this 
population had arsenic-related disease [47]. De Chaudhuri et al. [48] hypothesized that low occurrence 
of the disease may be related to the genetic variability. Hence, the association of exonic genetic 
polymorphisms in AS3MT with the occurrence of arsenic-induced skin lesions was investigated. They 
first analyzed 13 genotypes in AS3MT in 25 cases with skin lesions and 25 controls from North 24 
Parganas, Nadia, and Murshidabad Districts in West Bengal, and identified eight common genotypes. 
Mean concentrations of arsenic in drinking water and human urine were 163.16 μg/L and 301.17 μg/L, 
respectively, in the cases with skin lesions, and 161.71 μg/L and 283.28 μg/L, respectively, in controls. 
For these samples, there were no significant differences in the arsenic concentrations between case and 
control groups. On the other hand, arsenic concentrations in nail and hair of case subjects (5.39 μg/g 
dry wt and 3.13 μg/g dry wt, respectively) were significantly higher than those of control group   
(2.39 μg/g dry wt and 1.61 μg/g dry wt, respectively). The authors did not carry out urinary arsenic 
speciation and thus they did not mention arsenic methylation. Among the identified eight genotypes, 
AS3MT 14458 (rs11191439) was genotyped in 229 cases and 199 controls, and the distribution of 
genotype frequencies was compared between cases and controls. However, no significant difference 
was detected between the two groups, and thus the exonic genetic polymorphisms in AS3MT may not 
be linked to the occurrence of arsenic-induced skin lesions.  
3.2.6. Taiwan 
Chung et al. [49] attempted to evaluate the impact of AS3MT 12390 (rs3740393) in intron 6 on the 
cancer prevalence in arsenic-endemic areas of Taiwan. The authors conducted a 15 years follow-up 
study (1988–2004) in Homei, Funshin, and Hsinming villages in Putai Township of Chiayi County, 
where the highest prevalence of Black Footed Disease has been observed. During these 15 years, total 
arsenic concentration, %IA, and %MMA[V] significantly decreased, while contrasting results were 
observed for %DMA[V], (MMA[V] + DMA[V])/total arsenic, and DMA[V]/MMA[V]. Individuals 
with higher %MMA[V] in 1988 and with little change in %MMA[V] during these 15 years had higher 
cancer risk, but its significance level was low (p < 0.1). These results imply that %MMA[V] is a 
potential predictor of the cancer risk. Seventeen cases with cancers identified by the National Cancer 
Registry Systems and 191 controls were investigated, but AS3MT 12390 (rs3740393) showed no 
significant effect on the cancer risk. On the other hand, a general linear model (GLM), which was 
adjusted for age, sex, and education level, revealed that AS3MT 12390 (rs3740393) GC genotype had 
lower %MMA[V] and higher %DMA[V] and DMA[V]/MMA[V] than the GG genotype. This suggests 
that the GC carrier may have a higher methylation capacity from MMA to DMA and this SNP may be 
an indicator of individual cancer susceptibility in relation to MMA%. 
3.2.7. Vietnam 
Arsenic pollution in groundwater in Vietnam was reported by Berg et al [50]. The authors detected 
more than 3,000 μg/L of As concentration in groundwater from around Hanoi. Following this initial 
attempt, many studies have reported the concentration and distribution patterns of As in groundwater 
and sediment samples in northern and southern Vietnam [51–56]. Int. J. Mol. Sci. 2011, 12      
 
2360
While intensive studies have focused on the levels of arsenic in environmental samples, there is 
little information on arsenic exposure to, and toxic impacts on, local residents [18,53,57–61]. 
Furthermore, frequency distribution of AS3MT polymorphisms and the association with arsenic 
methylation ability have not yet been clarified. Hence, our group has investigated arsenic exposure, 
methylation capacity, and SNPs in AS3MT in Vietnamese [17–21]. 
To clarify the relationship between arsenic methylation and SNPs in AS3MT, we collected 
groundwater as well as human hair, urine, and blood samples from Hoa Hau and Liem Thuan in Ha 
Nam Province, which are located in the Red River Delta. For the human samples, each arsenic 
compound was quantified and 17 SNPs in AS3MT were genotyped [17,18,20]. The arsenic level in 
filtered water that some families consumed in Hoa Hau drastically (around 93%) decreased when 
compared with that in raw groundwater. Geometric means (GMs) of arsenic concentration in drinking 
water (50.1 μg/L) and human hair (0.351 μg/g dry wt) from Hoa Hau were significantly higher than 
those from Liem Thuan (1.7 μg/L in the water and 0.232 μg/g dry wt in the hair). On the other hand, 
there was no significant difference in urinary arsenic level and composition of arsenicals between Hoa 
Hau (GM, 92.6 μg/g creatinine) and Liem Thuan (GM, 97.9 μg/g creatinine), suggesting that the 
residents in Hoa Hau have not recently been exposed to arsenic through drinking water and/or there are 
arsenic sources other than drinking water in Liem Thuan. Among the 17 SNPs in AS3MT investigated, 
14 unexonic SNPs were categorized into four LD clusters; AS3MT 3963 (rs7098825), 6144 
(rs17878846), 12390 (rs3740393), 14215 (rs3740390), 35587 (rs11191453), and 37950 (rs17879819) 
as cluster 1, AS3MT 4602 (rs7085104), 35991 (rs10748835), and 37853 (rs11191459) as cluster 2, 
AS3MT 4740 (rs12416687) and 12590 (rs3740392) as cluster 3, and AS3MT 5913 (rs4917986), 9749 
(rs17881367), and 27215 (rs11191446) as cluster 4. We also found that sex, age, and body mass index 
(BMI) are correlated with urinary arsenic profile in this Vietnamese population. Thus, to understand 
the SNP-dependent association with arsenic metabolism without co-effects, we further conducted an 
analysis that was adjusted for sex, age, and BMI and detected significant associations for 12 SNPs. In 
cluster 1, homozygotes in AS3MT 12390 (rs3740393) GG and 35587 (rs11191453) CC had lower 
DMA[V]/MMA[V] in the urine, suggesting low methylation capacity from MMA to DMA for homo 
types of these SNPs. All homozygotes for AS3MT 4602 (rs7085104) GG, 35991 (rs10748835) AA, and 
37853 (rs11191459) AA in cluster 2 had lower %DMA[V] in the urine, when compared with other 
genotypes in the corresponding SNP. For AS3MT 37853 (rs11191459), %MMA[V] in AA homozygote 
was lower than in GG type. LD cluster 3 (AS3MT 4740 (rs12416687) and 12590 (rs3740392)) showed 
significant associations with urinary %DMA[V]. For AS3MT 12590 (rs3740392), the TT type had a 
higher DMA[V]/MMA[V] ratio in urine than other genotypes, suggesting the prompted second 
methylation capacity. The LD group including AS3MT 5913 (rs4917986), 9749 (rs17881367), and 
27215 (rs11191446) (cluster 4) had a correlation with %MMA[V]. For AS3MT 5913 (rs4917986), TC 
type had a higher MMA[V]/IAs than TT type, suggesting that the SNP may be related to the first 
methylation process of As. AS3MT 27215 (rs11191446) AA had a higher DMA[V]/MMA[V] and a 
lower MMA[V]/IA than SNP27215 (rs11191446) AG. Apart from LD clusters, AS3MT 8979 
(rs7920657) AA showed a low %DMA[V] compared with other genotypes. Heterozygote for exonic 
AS3MT 14458 (rs11191439, Met287Thr) TC had a higher MMA[V]/IAs in urine than TT homozygote, 
indicating that the heterozygote may have a stronger methylation ability of IAs.  Int. J. Mol. Sci. 2011, 12      
 
2361
4. Allele Frequency of SNPs in AS3MT 
As we have mentioned above, several SNPs in AS3MT may influence arsenic metabolism. 
However, only limited information on frequencies of genetic polymorphisms in AS3MT was available 
for the number of the SNPs and the association with ethnicity. We have reported distribution of SNPs 
in AS3MT in some Asian [Japanese (JP), South Koreans (SKR), Chinese (CH), Mongolians (MN), 
Tibetans (TIB), Nepalese (NP), Vietnamese (VN), Sri Lanka-Tamils (SLT), Sri Lanka-Sinhalese 
(SLS)] and African [Ovambos (OVA) and Ghanaians (GH)] populations since 2007 [18,20,62–65].  
The summarized results are shown in Table 1. The genotype frequencies followed the   
Hardy–Weinberg Principle except for 4602 (rs7085104) in MN, 6144 (rs17878846) in CH and TIB, 
7395 (rs12767543) in SKR and VN, 9749 (rs17881367) in MN, 12390 (rs3740393) in JP, 12590 
(rs3740392) in JP, 14215 (rs3740390) in JP, SKR, MN, and GH, 26790 (rs11191445) in JP, 35587 
(rs11191453) in JP, SKR, MN, TIB, and VN, 37616 (rs4568943) in JP, CH, Mongolians, and OVA, 
and 37950 (rs17879819) in OVA. Because no genotyping error was observed in duplicate analysis, the 
reason that some genotype frequencies did not follow the Hardy–Weinberg Principle may probably be 
due to the small sample size. The allele frequencies of SNPs of Japanese in Tokyo, Japan (JPT (J)), 
Han Chinese in Beijing, China (CHB (H)), Chinese in Metropolitan Denver, Colorado (CHD (D)), 
Luhya in Webuye, Kenya (LWK (L)), Maasai in Kinyawa, Kenya (MKK (K)), Yoruban in Ibadan, 
Nigeria (YRI (Y)), African ancestry in Southwest USA (ASW (A)), Tuscan in Italy (TSI (T)), Utah 
residents with Northern and Western European ancestries from the CEPH collection (CEU (C)), 
Gujarati Indians in Houston, Texas (GIH (G)), and Mexican ancestry in Los Angeles, California (MEX 
(M)) that are available in the International HapMap Project [31], were compared with our studies 
(Figure 3). While the distribution patterns of AS3MT 4602 (rs7085104), 9749 (rs17881367), 12390 
(rs3740393), 12590 (rs3740392), and 27215 (rs11191446) polymorphisms were not drastically 
different among the populations, notable variations were found for other SNPs. For AS3MT 3963 
(rs7098825), C alleles were low in SLT, SLS, OVA, GH, YRI (Y) and CEU (C), particularly in MN. 
NP has no C allele of AS3MT 4740 (rs12416687). Relatively high frequencies of AS3MT 7395 
(rs12767543) A allele and 8979 (rs72920657) A allele were found in CH and VN, respectively. 
AS3MT 6144 (rs17878846) A allele, AS3MT  37616 (rs4568943) A allele, and AS3MT 37950 
(rs17879819) C allele frequencies in OVA and GHA populations were higher than Asians, but 
comparable with those in MN. Frequencies of AS3MT 10209 (rs3740394) A allele, AS3MT 26790 
(rs11191445) C allele, and AS3MT 35991 (rs10748835) A allele in Asians (except for AS3MT 35991 
(rs10748835) A allele in OVA) were higher than those in other ethnic groups, while the opposite trend 
was observed for AS3MT (rs11191439) T allele. For AS3MT 14215 (rs3740390), the allele distribution 
was different even within Chinese (CH vs CHB(H) and CHD(D)) and African groups (OVA and GH 
vs LWK(L), MKK(K), YRI(Y), and ASW(A)). TIB also showed a different pattern of AS3MT 14215 
(rs3740390) allele from other Asian populations. Relatively lower C allele frequency of AS3MT 25986 
(rs7085854) was detected in JP, JPT, SKR, and MN. TIB showed different allele distribution of 
AS3MT 35587 (rs11191446). To understand these variations, further research is necessary. Int. J. Mol. Sci. 2011, 12      
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Table 1. Allele frequency of genotypes in AS3MT of various Asians and Africans [18,20,62–65]. 
SNP ID  rs #  Location 
Nucleotide 
change 
Ancestral  Allele 
Japanese 
(n = 141) 
South 
Koreans 
(n = 230) 
Chinese 
(n = 54) 
Mongolians 
(n = 58) 
Tibetans 
(n = 65) 
Nepalese 
(n = 31) 
3963  rs7098825  5’ terminal  C/T  T  C  0.266   0.298   0.241   0.009   0.331   0.355  
T  0.734   0.702   0.759   0.991   0.669   0.645  
4602  rs7085104  5’ terminal  A/G  A  A  0.567   0.565   0.436   0.672*  0.454   0.694  
G  0.433   0.435   0.565   0.327*  0.546   0.307  
4740  rs12416687  5’ terminal  C/T  T  C  0.060   0.067   0.130   0.061   0.054   0.000  
T  0.940   0.933   0.871   0.940   0.946   1.000  
5913  rs4917986  Intron 3  C/T  T  C  NA  NA  NA  NA  NA  NA 
T  NA  NA  NA  NA  NA  NA 
6144  rs17878846  Intron 3  A/T  A  A  0.734   0.730   0.695*  0.931   0.708*  0.678  
T  0.266   0.270   0.306*  0.069   0.292*  0.323  
7395  rs12767543  Intron 3  A/G  G  A  0.287   0.274*  0.426   0.069   0.185   0.275  
G  0.713   0.727*  0.574   0.931   0.815   0.726  
8979  rs7920657  Intron 5  A/T  T  A  0.057   0.076   0   0.077   0.069   0.000  
T  0.944   0.924   1.000   0.922   0.931   1.000  
9749  rs17881367  Intron 5  A/G  A  A  0.944   0.924   1.000   0.922*  0.931   1.000  
G  0.057   0.076   0   0.077*  0.069   0.000  
10209  rs3740394  Intron 6  A/G  T  A  0.990   0.985   1.000   0.983   0.985   0.984  
G  0.011   0.015   0   0.017   0.016   0.016  
12390  rs3740393  Intron 6  C/G  C  C  0.373*  0.279   0.278   0.431   0.338   0.339  
G  0.628*  0.722   0.722   0.569   0.662   0.661  
12590  rs3740392  Intron 7  C/T  T  C  0.178*  0.172   0.251   0.215   0.185   0.162  
T  0.823*  0.829   0.751   0.784   0.816   0.839  
14215  rs3740390  Intron 8  C/T  C  C  0.483*  0.587*  0.343   0.587*  0.262   0.645  
T  0.518*  0.413*  0.658   0.414*  0.739   0.355  
14458
1  rs11191439  Exon 9  C/T  T  C  0.004   0.009   0   0.026   0.023   0.000  
T  0.997   0.992   1.000   0.974   0.977   1.000  Int. J. Mol. Sci. 2011, 12      
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Table 1. Cont. 
25986  rs7085854  Intron 8  C/T  T  C  0.057   0.122   0.259   0.052   0.162   0.145  
T  0.944   0.879   0.741   0.949   0.839   0.855  
26790  rs11191445  Intron 10  C/T  C  C  0.990*  0.985   1.000   0.983   0.977   0.968  
T  0.011*  0.015   0   0.017   0.023   0.033  
27215  rs11191446  Intron 10  A/G  A  A  0.926   0.918   0.972   0.949   0.900   0.952  
G  0.075   0.083   0.028   0.052   0.100   0.049  
35587  rs11191453  Intron 10  C/T  T  C  0.344*  0.370*  0.333   0.155*  0.516*  0.404  
T  0.656*  0.631*  0.666   0.845*  0.485*  0.597  
35991  rs10748835  Intron 10  A/G  A  A  0.543   0.570   0.602   0.561   0.654   0.597  
G  0.457   0.431   0.398   0.440   0.346   0.404  
37616  rs4568943  3’ terminal  A/C  A  A  0.656*  0.735   0.519*  0.906*  0.639   0.678  
C  0.344*  0.266   0.482*  0.095*  0.362   0.323  
37853  rs11191459  3’ terminal  A/G  G  A  NA  NA  NA  NA  NA  NA 
G  NA  NA  NA  NA  NA  NA 
37950  rs17879819  3’ terminal  C/T  C  C  0.710   0.713   0.676   0.923   0.638   0.629  
T  0.291   0.287   0.324   0.078   0.361   0.371  
References  [65]  [65]  [65]  [65]  [65]  [65] 
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Table 1. Cont. 
SNP ID  rs #  Location 
Nucleotide
change 
Ancestral  Allele 
Vietnamese 
(n = 100) 
Sri Lanka-
Tamils 
(n = 29) 
Sri Lanka-
Sinhalese 
(n = 30) 
Ovambos 
(n = 102) 
Ghanaians 
(n = 87) 
3963  rs7098825  5’ terminal  C/T  T  C  NA  0.086   0.117   0.054   0.121  
T  NA  0.914   0.883   0.946   0.879  
4602  rs7085104  5’ terminal  A/G  A  A  0.420   0.845   0.817   0.525   0.598  
G  0.580   0.155   0.184   0.475   0.403  
4740  rs12416687  5’ terminal  C/T  T  C  0   0.017   0.017   0.133   0.104  
T  0.720   0.983   0.984   0.868   0.897  
5913  rs4917986  Intron 3  C/T  T  C  0.080   NA  NA  NA  NA 
T  0.920   NA  NA  NA  NA 
6144  rs17878846  Intron 3  A/T  A  A  0.750   0.845   0.867   1.000   1.000  
T  0.250   0.155   0.134   0   0  
7395  rs12767543  Intron 3  A/G  G  A  0.335*  0.121   0.167   0.113   0.304  
G  0.665*  0.880   0.834   0.888   0.695  
8979  rs7920657  Intron 5  A/T  T  A  0   0.035   0.017   0.142   0.075  
T  0.590   0.966   0.984   0.858   0.926  
9749  rs17881367  Intron 5  A/G  A  A  NA  0.966   0.984   0.858   0.926  
G  NA  0.035   0.017   0.142   0.075  
10209  rs3740394  Intron 6  A/G  T  A  NA  0.983   0.984   0.868   0.920  
G  NA  0.017   0.017   0.133   0.081  
12390  rs3740393  Intron 6  C/G  C  C  0.225   0.189   0.251   0.540   0.299  
G  0.775   0.810   0.751   0.461   0.702  
12590  rs3740392  Intron 7  C/T  T  C  0.360   0.155   0.084   0.221   0.189  
T  0.640   0.845   0.917   0.780   0.810  
14215  rs3740390  Intron 8  C/T  C  C  0.755   0.810   0.867   0.554   0.414* 
T  0.245   0.189   0.134   0.446   0.587* 
14458
1  rs11191439  Exon 9  C/T  T  C  0   0   0.017   0.093   0.075  
T  0.980   1.000   0.984   0.907   0.926  Int. J. Mol. Sci. 2011, 12      
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25986  rs7085854  Intron 8  C/T  T  C  NA  0.172   0.250   0.299   0.316  
T  NA  0.828   0.750   0.701   0.684  
26790  rs11191445  Intron 10  C/T  C  C  NA  0.983   0.984   0.814   0.966  
T  NA  0.017   0.017   0.186   0.035  
27215  rs11191446  Intron 10  A/G  A  A  NA  0.966   0.984   0.873   0.920  
G  NA  0.035   0.017   0.128   0.081  
35587  rs11191453  Intron 10  C/T  T  C  0.270*  0.207   0.134   0.045   0.063  
T  0.730*  0.793   0.867   0.957   0.937  
35991  rs10748835  Intron 10  A/G  A  A  0.585   0.535   0.367   0.706   0.402  
G  0.415   0.466   0.633   0.294   0.598  
37616  rs4568943  3’ terminal  A/C  A  A  NA  0.794   0.867   0.941*  0.931  
C  NA  0.207   0.134   0.059*  0.069  
37853  rs11191459  3’ terminal  A/G  G  A  0.495   NA  NA  NA  NA 
G  0.505   NA  NA  NA  NA 
37950  rs17879819  3’ terminal  C/T  C  C  NA  0.793   0.867   0.961*  0.937  
T  NA  0.207   0.134   0.040*  0.063  
References  [20]  [65]  [65]  [65]  [65] 
NA: no available data. 
*: not followed Hardy–Weinberg Principle (p < 0.05). 
1: Met to Thr substitution at amino acid base on 287. 
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Figure 3. Frequencies of alleles in AS3MT in various populations reported in our   
studies [20,65] and the HapMap Project [31]. JP: Japanese, JPT (J): Japanese in Tokyo, 
Japan, SKR: South Koreans, CH: Chinese, CHB (H): Han Chinese in Beijing, China,   
CHD (D): Chinese in Metropolitan Denver, Colorado, MN: Mongolians, TIB: Tibetans, 
NP: Nepalese, VN: Vietnamese, SLT: Sri Lanka-Tamils, SLS: Sri Lanka-Sinhalese, OVA: 
Ovambos, GH: Ghanaians, LWK (L): Luhya in Webuye, Kenya, MKK (K): Maasai in 
Kinyawa, Kenya, YRI (Y): Yoruban in Ibadan, Nigeria, ASW (A): African ancestry in 
Southwest USA, TSI (T): Tuscan in Italy, CEU (C): Utah residents with Northern and 
Western European ancestry from the CEPH collection, GIH (G): Gujarati Indians in 
Houston, Texas, MEX (M): Mexican ancestry in Los Angeles, California. 1; Fujihara et al. [65], 
2; Agusa et al. [20], 3; HapMap Project [31]. 
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5. Conclusions and Future Perspectives 
In this review, we summarized recent results on association of AS3MT genetic polymorphism with 
arsenic methylation. Although there are some inconsistencies between the genotypes and metabolism 
in human case studies, we found consistent results on two SNPs, AS3MT 12390 (rs3740393) in intron 
and 14458 (rs11191439, Met287Thr) in exon, in all the nations (Figure 4 and Table 2). This indicates 
that these SNPs may be ethnically independent polymorphisms, but may affect arsenic methylation.  
AS3MT 12390 (rs3740393) is an intronic polymorphism, but the genotype with C allele in this SNP 
may have a higher second methylation capacity as predicted from the consistent results of high 
DMA[V]/MMA[V] in Mexicans, Argentines, Taiwanese, and Vietnamese (Table 2). Although AS3MT 
12390 (rs3740393) belongs to a LD cluster in these populations, other SNPs within the cluster are 
different among populations (Table 2). Therefore, AS3MT 12390 (rs3740393) may be involved in an 
independent reaction from other SNPs in the same LD on a worldwide population basis. The frequency 
of AS3MT 12390 (rs3740393) CC or CG types was much higher than the GG type in Argentina’s 
population; the allele frequencies of C and G were 72% and 28%, respectively [40]. This allele 
frequency distribution was drastically different from other populations (Table 1 and Figure 3). This 
unique distribution may contribute to the results indicating that Argentina’s population has a higher 
%DMA and a lower %MMA in the urine, when compared with yet another study [15]. It is noteworthy 
to study whether this specific genotype distribution of AS3MT 12390 (rs3740393) is observed only in 
this group (Argentinean Andes) and how this unique SNP selection took place. 
Figure 4. Suspected universal AS3MT genotype-dependent methylation of arsenic. C 
carrier of AS3MT 14458 (rs11191439) may have higher first methylation capacity than the 
T carrier, while C carrier of AS3MT 12390 (rs3740393) may have higher second 
methylation capacity than the G carrier.  
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Table 2. Differences in the association of arsenic methylation and linkage disequilibrium (LD) for SNPs of AS3MT among nations. 
SNP ID  rs #  Location 
Nucleotide
change 
Ancestral 
Mexico 
(n = 144) 
Mexico 
(n = 122) 
Mexico 
(n = 405) 
Argentina 
(n = 147) 
3963  rs7098825  5' terminal  C/T  T         
4602  rs7085104  5' terminal  A/G  A  NS  %MMA[III + V]:  
AA + AG > GG 
%DMA[III + V]:  
GG > AA + AG 
DMA[III + V]/MMA[III + V]:  
GG > AA + AG 
   
4740  rs12416687  5' terminal  C/T  T  NS       
4965  rs17881215  Exon 1: 
5' UTR 
C/G  G         
5019  rs17880342  Exon 1: 
5' UTR 
C/T  C        NA 
5051  rs17883409  Intron 1  *  NAV  NS      NA 
5194  rs3740400  Intron 1   A/C  C        NA 
5913  rs4917986  Intron 3   C/T  T         
6144  rs17878846  Intron 3   A/T  A         
7395  rs12767543  Intron 3   A/G  G  DMA[V]/MMA[V]:  
AA + AG > GG
2 
  S   
8788  rs17881367  Intron 5   -/TTT  NAV        NA 
8979  rs7920657  Intron 5   A/T  T         
9749  rs17881367  Intron 5   A/G  A         
10209  rs3740394  Intron 6   C/T  T  NS       
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12390  rs3740393  Intron 6   C/G  C  DMA[V]/MMA[V]:  
CC + CG > GG
2 
  S  %MMA[V]:  
GG > CC, CG 
%DMA[V]:  
CC, CG > GG 
DMA[V]/MMA[V]:  
CC, CG > GG 
12590  rs3740392  Intron 7   C/T  T  NS      NA 
13599  rs10883797  Intron 7   C/G  C  NS       
14215  rs3740390  Intron 8  C/T  C      S  %MMA[V]:  
CC > TT, CT 
%DMA[V]:  
TT, CT > CC 
DMA[V]/MMA[V]:  
TT, CT > CC 
14458
1  rs11191439  Exon 9  C/T  T    %MMA[III + V]:  
CT + CC > TT 
%As[V]:  
CT + CC > TT 
NS  NA 
25986  rs7085854  Intron 9  C/T  T  NS       
27215  rs11191446  Intron 10  A/G  A         
30312  rs1191453  Intron 10  C/T  T      DMA[V]/MMA[V]: 
CC > CT > TT 
 
35587  rs11191453  Intron 10  C/T  T  DMA[V]/MMA[V]:  
CC + CT > TT
2 
MMA[V]/As[III]:  
TT > CC + CT
2 
NS  S   
35739  rs11191454  Intron 10  A/G  A      S   
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35991  rs10748835  Intron 10  A/G  A        %MMA[V]:  
GG > AA, AG 
%DMA[V]:  
AA, AG > GG 
DMA[V]/MMA[V]:  
AA, AG > GG 
36209  rs17879039  Exon 11: 
3' UTR 
A/G  G         
37219  rs1046778  Exon 11: 
3' UTR 
C/T  T      S   
37616  rs4568943  3' terminal  A/C  A         
37853  rs11191459  3' terminal  A/G  G         
37950  rs17879819  3' terminal  C/T  C         
LD cluster               
LD1          7395-12390-35587     7395-12390-14215-
30312 
-35587-35739-
37219 
12390-14215-35991  
LD2                 
LD3                 
LD4                 
References        [35, 36]  [37]  [38]  [40] 
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SNP ID  rs #  Location 
Nucleotide 
change 
Ancestral 
Argentina 
(n = 104) 
Chile 
(n = 50) 
Chile 
(n = 207) 
3963  rs7098825  5' terminal  C/T  T       
4602  rs7085104  5' terminal  A/G  A  %MMA[V]:  
AA + AG > GG 
%DMA[V]: 
GG > AG + AA 
   
4740  rs12416687  5' terminal  C/T  T       
4965  rs17881215  Exon 1: 
5' UTR 
C/G  G    %MMA:  
CG > GG 
 
5019  rs17880342  Exon 1: 
5' UTR 
C/T  C       
5051  rs17883409  Intron 1  *  NAV       
5194  rs3740400  Intron 1   A/C  C  %MMA[V]:  
AA + AC > CC 
%DMA[V]:  
CC > AC + AA 
NS   
5913  rs4917986  Intron 3   C/T  T       
6144  rs17878846  Intron 3   A/T  A       
7395  rs12767543  Intron 3   A/G  G       
8788  rs17881367  Intron 5   -/TTT  NAV       
8979  rs7920657  Intron 5   A/T  T       
9749  rs17881367  Intron 5   A/G  A       
10209  rs3740394  Intron 6   C/T  T       
12390  rs3740393  Intron 6   C/G  C       
12590  rs3740392  Intron 7   C/T  T       
13599  rs10883797  Intron 7   C/G  C       
14215  rs3740390  Intron 8  C/T  C       
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14458
1  rs11191439  Exon 9  C/T  T    %MMA: 
CT + CC > TT 
%MMA:  
CT + CC > TT 
25986  rs7085854  Intron 9  C/T  T       
27215  rs11191446  Intron 10  A/G  A       
30312  rs1191453  Intron 10  C/T  T       
35587  rs11191453  Intron 10  C/T  T       
35739  rs11191454  Intron 10  A/G  A       
35991  rs10748835  Intron 10  A/G  A       
36209  rs17879039  Exon 11: 
3' UTR 
A/G  G    NS   
37219  rs1046778  Exon 11: 
3' UTR 
C/T  T       
37616  rs4568943  3' terminal  A/C  A       
37853  rs11191459  3' terminal  A/G  G       
37950  rs17879819  3' terminal  C/T  C       
LD cluster             
LD1          4602-5194-12390 
-14215-35991
3 
4965-14458   
LD2               
LD3               
LD4               
References        [43]  [44]  [45] 
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Table 2. Cont. 
SNP ID  rs #  Location 
Nucleotide 
change 
Ancestral 
Central Europe
4 
(n = 415) 
Taiwan 
(n = 208) 
Vietnam 
(n = 100) 
3963  rs7098825  5' terminal  C/T  T      NS 
4602  rs7085104  5' terminal  A/G  A      %DMA[V]:  
AA, AG > GG 
4740  rs12416687  5' terminal  C/T  T      %DMA[V]:  
TT > CT, CC 
4965  rs17881215  Exon 1: 
5' UTR 
C/G  G       
5019  rs17880342  Exon 1: 
5' UTR 
C/T  C       
5051  rs17883409  Intron 1  *  NAV       
5194  rs3740400  Intron 1   A/C  C       
5913  rs4917986  Intron 3   C/T  T      %MMA[V]:  
CT > TT 
6144  rs17878846  Intron 3   A/T  A      NS 
7395  rs12767543  Intron 3   A/G  G      NS 
8788  rs17881367  Intron 5   -/TTT  NAV       
8979  rs7920657  Intron 5   A/T  T      %DMA[V]:  
AT, TT > AA 
9749  rs17881367  Intron 5   A/G  A      %MMA[V]:  
AG > AA 
10209  rs3740394  Intron 6   C/T  T       
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12390  rs3740393  Intron 6   C/G  C    %MMA[V]:  
GG > CG 
%DMA[V]:  
CG > GG 
DMA[V]/MMA[V]: 
CG > GG 
%MMA[V]:  
GG > CC 
DMA[V]/MMA[V]:  
CG > GG 
12590  rs3740392  Intron 7   C/T  T      %DMA[V]:  
TT > CC 
DMA[V]/MMA[V]: 
TT > CC 
13599  rs10883797  Intron 7   C/G  C       
14215  rs3740390  Intron 8  C/T  C      NS 
14458
1  rs11191439  Exon 9  C/T  T  %DMA[V]:  
TT > CT + CC 
%MMA[V]: 
CT + CC > TT 
  MMA[V]/IA:  
CT > TT  
25986  rs7085854  Intron 9  C/T  T       
27215  rs11191446  Intron 10  A/G  A      %MMA[V]:  
AG > AA 
DMA[V]/MMA[V]:  
AA > AG 
MMA[V]/IA:  
AG > AA 
30312  rs1191453  Intron 10  C/T  T       
35587  rs11191453  Intron 10  C/T  T      DMA[V]/MMA[V]:  
CT > TT 
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35739  rs11191454  Intron 10  A/G  A       
35991  rs10748835  Intron 10  A/G  A      %DMA[V]:  
AG > AA 
36209  rs17879039  Exon 11: 
3' UTR 
A/G  G       
37219  rs1046778  Exon 11: 
3' UTR 
C/T  T       
37616  rs4568943  3' terminal  A/C  A       
37853  rs11191459  3' terminal  A/G  G      %DMA[V]:  
GG, AG > AA 
%MMA[V]:  
GG > AA 
37950  rs17879819  3' terminal  C/T  C      NS 
LD cluster             
LD1              3963-6144-12390 
-14215-35587-37950 
LD2              4602-35991-37853  
LD3              4740-12590  
LD4              5913-9749-27215 
References        [46]  [49]  [18, 20] 
NAV: not available. 
NS: not significant. 
NA: no statistical analysis due to the small genotype frequency. 
1: Met to Thr substitution at amino acid base on 287. 
2: Significant result was observed for only children but not for adults. 
3: Previous data of SNP is included. 
4: Hungarian, Romanian, and Slovak. 
*: -/CGCGCCCTGAGTCGCAGGCCGAGGAGACAGTGAGTGC 
S: Significant association with DMA[V]/MMA[V] was found but no information which genotype is associated with it. Int. J. Mol. Sci. 2011, 12      
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AS3MT 14458 (rs11191439), locates in the exon region, is synonymous substitution (Met to Thr 
substitution) at the amino acid base 287, and its functional difference has been investigated in some 
studies. By reviewing the in vitro [30,34] and human case studies [17–21,35–40,43–49], we found that 
C allele containing genotype in this SNP consistently showed a higher first methylation capacity than 
the T allele carrier. Interestingly, the effect of this SNP has been observed even in subjects exposed to 
low levels of arsenic [46]. Hence, it seems that the association of AS3MT 14458 polymorphism with 
arsenic methylation may occur irrespective of arsenic exposure status. This allele frequency was 
relatively low in Asian populations (Table 1 and Figure 3), indicating that among different global 
populations, Asians may be genetically less sensitive to arsenic methylation. 
Increased %MMA in the urine linked to cancer risk has been suggested in previous epidemiological 
studies [9–12]. Thus, AS3MT 14458 (rs11191439) C allele carriers, who have a higher methylation 
capacity from IA to MMA, may be at higher risk of arsenic related cancers. The association of this 
SNP with human health effect was investigated in Mexicans [37] and Indians [48]. According to the 
study by De Chaudhuri et al. [48], there was no significant interaction between this SNP and skin 
lesions. On the other hand, Valenzuela et al. [37] found higher frequency of C allele type of AS3MT 
14458 (rs11191439) TC + CC in people with cancers, although the level of significance was not high  
(p = 0.055). Hence, at present, no rigid evidence has been provided to link the AS3MT 14458 
(rs11191439) dependent variation in arsenic methylation to arsenic-induced carcinogenesis. Apart 
from an evidence of cancer, Sampayo-Reyes et al. [39] found that AS3MT 14458 (rs11191439) is 
linked with DNA damages among children living in arsenic contaminated sites in Mexico (p = 0.034). 
Although these authors did not analyze arsenic compounds in urine and thus did not take into 
consideration the methylation capacity, they suggested that increased production of MMA[III]   
during methylation processes in AS3MT 14458 (rs11191439, Met287Thr) C allele carrier might   
induce genotoxicity. 
Up to now, it still remains unknown how AS3MT 12390 (rs3740393) and 14458 (rs11191439) can 
influence the structure and function of this enzyme. Also, several results of AS3MT  
genotype-dependent arsenic methylation are interesting, because some non-exonic (intron, UTR, or 5’ 
and 3’ gene) SNPs may play important roles during methylation. The study on splicing variants of 
AS3MT gene and their function is one such issue to be pursued. 
There are several tasks for future study regarding the role of AS3MT polymorphisms on arsenic 
methylation. As shown in this review, most studies encompassed only a small number of subjects and 
SNPs in AS3MT and thus, they merely provide fragmental and weak significant results at particular 
level(s). As shown in Table 2, results on the genotype association of AS3MT 4602 (rs7085104), 5194 
(rs3740400), 7395 (rs12767543), 12590 (rs3740393), 14215 (rs3740390), 35587 (rs11191453), and 
35991 (rs10748835) with arsenic metabolism were not consistent among different country groups. 
Larger scale studies would be required to gain enough statistical power and strengthen currently 
proposed assumptions on the linkages of AS3MT SNPs with arsenic methylation and cancer risk. 
SNPs in AS3MT can provide useful information on the medical treatment of some diseases or risk 
assessment. For example, arsenic trioxide has been used for the treatment of acute promyelocytic 
leukemia, although the systematic mechanism is not fully understood [66]. The information on   
gene-arsenic interactions presented here can be applied to a personalized medicine for leukemia or 
other cancers. To better understand the variations in arsenic metabolism and to assess the potential Int. J. Mol. Sci. 2011, 12      
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susceptibility to its toxic and carcinogenic effects at individual and population levels, more 
comprehensive studies would be necessary. 
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